

GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Date: 27/09/2021

To,
The Manager
Listing Department
BSE Limited
Bombay Stock Exchange,
P. J. Towers, Dalal Street,
Mumbai - 400001

Subject: Submission pursuant to Regulation 51 (2) read with Schedule III of the SEBI (LODR), 2015

Ref: ISIN: INE88W07019 and scrip code 956084

Dear Sir/Madam,


This is to inform you that the non-convertible debentures bearing scrip code 956084 which are listed on BSE are due for redemption on 27th September, 2021. However, the Company is not in a position to service the principal repayment and redemption premium on the given due date.

Please note that the Company is in discussion with the Debenture Trustee in relation to this matter.

This above disclosure is being submitted to your good office pursuant to the Regulation 51 (2) read with Para A, Part B, Schedule III of the SEBI (LODR), 2015.

Kindly take the above information on records.

For Genlink Pharma Solutions Private Limited


Itishree Garg
Company Secretary and Compliance Officer
Membership No: A46259

